Clinical Trials Logo

Clinical Trial Summary

To compare the prognosis and adverse reactions of unresectable hepatocellular carcinoma receiving stereotactic radiotherapy combined with hepatic arterial chemoembolization and conversion hepatectomy


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05057104
Study type Observational
Source Beijing 302 Hospital
Contact Xuezhang Duan
Phone +8613621386161
Email [email protected]
Status Not yet recruiting
Phase
Start date October 10, 2021
Completion date December 31, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT05031949 - Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma Phase 1
Active, not recruiting NCT04592029 - TACE Combined With Sintilimab and Bevacizumab for Unresectable HCC Phase 1
Not yet recruiting NCT03283956 - Safety and Efficacy of dRug-ElutiNg beADs Trans-arterial chemoEmbolization for Hepatocellular Carcinoma in Taiwan N/A
Recruiting NCT03652467 - The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma Phase 1
Completed NCT03533920 - Clinical Trial to Evaluate the Efficacy and Safety of UNI-DEB for Unresectable Hepatocellular Carcinoma N/A
Not yet recruiting NCT04965454 - Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma Phase 2
Recruiting NCT04599790 - TACE Combined With Lenvatinib and Sintilimab for Advanced HCC Phase 2
Recruiting NCT04599777 - TACE Combined With Sorafenib and Tislelizumab for Advanced HCC Phase 2
Recruiting NCT02967887 - Evaluation of Hepatic Arterial Infusion of Cisplatin and 5-FU in Biomarker Stratified HCC Phase 2
Active, not recruiting NCT02989922 - A Study to Evaluate SHR-1210 in Subjects With Advanced HCC Phase 2
Recruiting NCT04273100 - PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC Phase 2
Withdrawn NCT03563170 - QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine Phase 1/Phase 2
Enrolling by invitation NCT04997850 - The Safety and Efficacy of Transarterial Chemoembolization (TACE) + Lenvatinib + Programmed Cell Death Protein 1 (PD-1) Antibody of Advanced Unresectable Hepatocellular Carcinoma Phase 1/Phase 2
Completed NCT03138031 - Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma N/A
Recruiting NCT03881501 - Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
Recruiting NCT03864211 - Thermal Ablation Followed by Immunotherapy for HCC Phase 1/Phase 2
Recruiting NCT04967482 - DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC N/A
Recruiting NCT04967495 - TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT N/A
Recruiting NCT04718909 - Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC Phase 2
Not yet recruiting NCT03807947 - Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma N/A